MX2023014722A - Forma cristalina de tolebrutinib y método de preparación y su uso. - Google Patents

Forma cristalina de tolebrutinib y método de preparación y su uso.

Info

Publication number
MX2023014722A
MX2023014722A MX2023014722A MX2023014722A MX2023014722A MX 2023014722 A MX2023014722 A MX 2023014722A MX 2023014722 A MX2023014722 A MX 2023014722A MX 2023014722 A MX2023014722 A MX 2023014722A MX 2023014722 A MX2023014722 A MX 2023014722A
Authority
MX
Mexico
Prior art keywords
tolebrutinib
preparation
crystal form
crystalline form
drug
Prior art date
Application number
MX2023014722A
Other languages
English (en)
Spanish (es)
Inventor
Jing Zhang
Minhua Chen
Jiaming Shi
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2023014722A publication Critical patent/MX2023014722A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2023014722A 2021-06-11 2022-06-02 Forma cristalina de tolebrutinib y método de preparación y su uso. MX2023014722A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202110652005 2021-06-11
CN202110690510 2021-06-22
CN202111326112 2021-11-10
PCT/CN2022/096779 WO2022257845A1 (zh) 2021-06-11 2022-06-02 Tolebrutinib的晶型及其制备方法和用途

Publications (1)

Publication Number Publication Date
MX2023014722A true MX2023014722A (es) 2024-02-13

Family

ID=84425691

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023014722A MX2023014722A (es) 2021-06-11 2022-06-02 Forma cristalina de tolebrutinib y método de preparación y su uso.

Country Status (12)

Country Link
US (1) US20250034130A1 (enExample)
EP (1) EP4353723A4 (enExample)
JP (1) JP2024521412A (enExample)
KR (1) KR20240021217A (enExample)
CN (1) CN117897381A (enExample)
AU (1) AU2022290946A1 (enExample)
BR (1) BR112023025841A2 (enExample)
CA (1) CA3221129A1 (enExample)
CO (1) CO2024000054A2 (enExample)
IL (1) IL309263A (enExample)
MX (1) MX2023014722A (enExample)
WO (1) WO2022257845A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3168146A1 (en) 2020-01-20 2021-07-29 Genzyme Corporation Therapeutic tyrosine kinase inhibitors for relapsing multiple sclerosis (rms)
CA3201936A1 (en) 2020-12-10 2022-06-16 Minhua Chen Crystal form of tolebrutinib and preparation method thereof
IL303834A (en) 2020-12-23 2023-08-01 Genzyme Corp 4-amino-3-(4-phenoxyphenyl)-1,3-dihydro-2H-imidazo[4,5-C]pyridin-2-one derivatives and their salts
CA3241687A1 (en) * 2021-12-21 2023-06-29 Tim Owens Crystalline forms of (r)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1h-imidazo[4,5-c]pyridin-2(3h)-one and salts thereof
US20250188076A1 (en) 2022-03-09 2025-06-12 Teva Pharmaceutical International Gmbh Solid state forms of tolebrutinib and of tolebrutinib salts
US20240238267A1 (en) * 2022-12-20 2024-07-18 Genzyme Corporation Drug formulations of (r)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1h-imidazo[4,5-c]pyridin-2(3h)-one
WO2026050513A1 (en) 2024-08-30 2026-03-05 Principia Biopharma Inc. Tolebrutinib for multiple sclerosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2004001034A1 (es) * 2003-05-14 2005-03-28 Teijin Pharma Ltd Formas cristalinas de acido 4-(1-((,etilbenzotiofen-3-il)me til)benzimidazol-2-iltio)butanoico; procedimiento de preparacion de las formas cristalinas; composicion farmaceutica; y su uso para el tratamiento de enfermedades inflamatorias, alergicas, r
EP3912979B1 (en) * 2015-06-03 2026-03-25 Principia Biopharma Inc. Tyrosine kinase inhibitors
EP3313811A1 (en) * 2015-06-26 2018-05-02 Aquinox Pharmaceuticals (Canada) Inc. Crystalline solid forms of the acetate salt of (1s,3s,4r)-4-((3as,4r,5s,7as)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1h-inden-5-yl)-3-(hydroxymethyl)-4-methylcyclohexanol
CN105753863B (zh) * 2015-09-11 2018-07-31 东莞市真兴贝特医药技术有限公司 氧代二氢咪唑并吡啶类化合物及其应用
CA3168146A1 (en) * 2020-01-20 2021-07-29 Genzyme Corporation Therapeutic tyrosine kinase inhibitors for relapsing multiple sclerosis (rms)

Also Published As

Publication number Publication date
IL309263A (en) 2024-02-01
KR20240021217A (ko) 2024-02-16
AU2022290946A1 (en) 2024-01-25
CO2024000054A2 (es) 2024-02-05
JP2024521412A (ja) 2024-05-31
US20250034130A1 (en) 2025-01-30
WO2022257845A1 (zh) 2022-12-15
BR112023025841A2 (pt) 2024-03-05
CN117897381A (zh) 2024-04-16
EP4353723A1 (en) 2024-04-17
EP4353723A4 (en) 2025-06-25
CA3221129A1 (en) 2022-12-15

Similar Documents

Publication Publication Date Title
CO2024000054A2 (es) Forma cristalina de tolebrutinib y método de preparación y su uso
EP4282486A3 (en) Complement factor b inhibitor, and pharmaceutical composition thereof, preparation method therefor and use thereof
AR126914A1 (es) Inhibidores de ras novedosos
MX2023006854A (es) Forma cristalina de tolebrutinib, metodo de preparacion y uso de la misma.
CO2026005655A2 (es) Inhibidor de pan-kras y uso del mismo en medicinas
JOP20210301A1 (ar) بيرولات ثلاثية الحلقة مكثفة كمُعدِّلات مضاد تريبسين ألفا-1
PE20240544A1 (es) Antagonista del receptor crf1 para el tratamiento de la hiperplasia suprarrenal congenita
BR0314379A (pt) Quinazolinonas espirocondensadas e a sua utilização como inibidores de fosfodiesterase
BR112014009102A2 (pt) compostos químicos
MX2022002603A (es) Proceso industrial para la preparacion de estetrol de alta pureza.
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
BRPI0515081A (pt) derivados de fenilaminopirimidina como inibidores de bcr-abl cinase
CL2023001367A1 (es) Inhibidores de btk
PH12019500681A1 (en) Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof
BRPI0512335A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e sua utilização
BRPI0409498A (pt) uso de um composto, formulação farmacêutica, composto, composição farmacêutica, e, processo para preparação de um composto
BRPI0409454A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com o receptor de glucagon e sua utilização
MX2023003576A (es) Compuesto como inhibidor de la akt cinasa.
BR112019003710A2 (pt) inibidor de pde7, composto, composição farmacêutica, uso de um inibidor de pde7 ou de um composto, e, método para tratar ou prevenir uma doença que é melhorada pela inibição de pde7.
BR112018069712A2 (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a.
BR112014001083A8 (pt) composto, processo para a preparação de um composto, composição farmacêutica, método para o tratamento de doenças e uso de um composto
MX2023003459A (es) Nuevos compuestos.
SA523441175B1 (ar) N-(2-(4- سيانو ثيازوليدين -3- يل)-2- أوكسو إيثيل)- كينولين -4- كربوكساميدات
BR112023017434A2 (pt) Derivados de 4-alcóxi-6-oxo-piridazina que modulam nlrp3
DOP2025000019A (es) Inhibidores de la proteasa principal de sars-cov2